Teachers Advisors LLC Raises Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Teachers Advisors LLC boosted its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 9.1% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 80,238 shares of the biopharmaceutical company’s stock after buying an additional 6,662 shares during the period. Teachers Advisors LLC’s holdings in Alnylam Pharmaceuticals were worth $4,112,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of the stock. TLP Group LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the first quarter worth approximately $380,000. Wellington Management Group LLP raised its stake in shares of Alnylam Pharmaceuticals by 0.3% in the first quarter. Wellington Management Group LLP now owns 12,041,179 shares of the biopharmaceutical company’s stock worth $617,111,000 after buying an additional 31,208 shares during the period. BB Biotech AG raised its stake in shares of Alnylam Pharmaceuticals by 4.2% in the first quarter. BB Biotech AG now owns 1,241,338 shares of the biopharmaceutical company’s stock worth $63,619,000 after buying an additional 50,000 shares during the period. AQR Capital Management LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth approximately $1,036,000. Finally, Candriam Luxembourg S.C.A. raised its stake in shares of Alnylam Pharmaceuticals by 11.7% in the first quarter. Candriam Luxembourg S.C.A. now owns 67,000 shares of the biopharmaceutical company’s stock worth $3,434,000 after buying an additional 7,000 shares during the period. Institutional investors own 88.96% of the company’s stock.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) opened at 81.885 on Tuesday. Alnylam Pharmaceuticals, Inc. has a 12 month low of $31.38 and a 12 month high of $86.92. The firm’s market cap is $7.06 billion. The firm’s 50-day moving average price is $80.45 and its 200-day moving average price is $59.96.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Friday, May 5th. The biopharmaceutical company reported ($1.25) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.22) by $0.03. Alnylam Pharmaceuticals had a negative return on equity of 42.90% and a negative net margin of 705.11%. The firm had revenue of $19 million for the quarter, compared to the consensus estimate of $22.91 million. During the same period in the prior year, the business earned ($1.21) EPS. Alnylam Pharmaceuticals’s quarterly revenue was up 160.3% compared to the same quarter last year. On average, equities research analysts expect that Alnylam Pharmaceuticals, Inc. will post ($5.19) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This article was posted by Markets Daily and is the property of of Markets Daily. If you are reading this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright law. The original version of this article can be viewed at https://www.themarketsdaily.com/2017/08/08/teachers-advisors-llc-raises-position-in-alnylam-pharmaceuticals-inc-nasdaqalny.html.

ALNY has been the topic of a number of research reports. ValuEngine upgraded Alnylam Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, June 2nd. Piper Jaffray Companies set a $116.00 price target on Alnylam Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, May 24th. Credit Suisse Group restated a “hold” rating and issued a $50.00 price target on shares of Alnylam Pharmaceuticals in a report on Tuesday, May 9th. Needham & Company LLC boosted their price target on Alnylam Pharmaceuticals from $68.00 to $98.00 and gave the company a “buy” rating in a report on Tuesday, June 27th. Finally, BidaskClub upgraded Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $79.79.

In other Alnylam Pharmaceuticals news, VP Michael Mason sold 9,375 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Tuesday, May 16th. The shares were sold at an average price of $70.00, for a total transaction of $656,250.00. Following the transaction, the vice president now owns 5,625 shares of the company’s stock, valued at approximately $393,750. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Akshay Vaishnaw sold 11,000 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Tuesday, May 23rd. The stock was sold at an average price of $75.00, for a total transaction of $825,000.00. Following the transaction, the executive vice president now directly owns 21,297 shares in the company, valued at approximately $1,597,275. The disclosure for this sale can be found here. In the last three months, insiders have sold 64,125 shares of company stock worth $4,325,000. Insiders own 4.30% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply